DV Trading LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH

DV Trading LLC purchased a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 26,551 shares of the company’s stock, valued at approximately $2,228,000.

Other institutional investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. lifted its holdings in Dianthus Therapeutics by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock valued at $3,135,000 after acquiring an additional 139 shares during the last quarter. First Horizon Corp purchased a new position in Dianthus Therapeutics in the first quarter worth approximately $32,000. Virtus Investment Advisers LLC increased its stake in Dianthus Therapeutics by 7.1% during the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after acquiring an additional 416 shares during the last quarter. Royal Bank of Canada increased its stake in Dianthus Therapeutics by 36.9% during the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after acquiring an additional 542 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock opened at $106.92 on Friday. Dianthus Therapeutics, Inc. has a fifty-two week low of $18.08 and a fifty-two week high of $114.55. The firm has a 50 day moving average price of $92.63 and a 200 day moving average price of $78.34. The company has a market capitalization of $5.85 billion, a PE ratio of -25.89 and a beta of 1.20.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. As a group, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on DNTH shares. Wedbush upped their price target on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Raymond James Financial reissued a “strong-buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $117.82.

Insider Activity

In other news, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the sale, the executive vice president directly owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Adam M. Veness sold 30,000 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the sale, the senior vice president owned 30,000 shares in the company, valued at $2,424,000. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 87,779 shares of company stock valued at $7,985,235. 3.02% of the stock is currently owned by corporate insiders.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.